Skip to content

TG Therapeutics

US · TGTX #1638 by market cap Listed 1970
63.34 -1.54 -2.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 17 in the most recent period (2026/Q3).
  • Total institutional ownership rose 4.6 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
88.72% +4.59pp
Institutions
521 +17
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund63.19%
Hedge Fund14.80%
Public Company6.14%
Individual/Insider4.68%
Private Company1.73%
Government Pension Fund1.66%
Insurance Company0.93%
Family Office/Trust0.22%
Other6.62%

Top holders as of 2026-09-30

BlackRock 16.16% · 22.63M sh
State Street Global Advisors 5.98% · 8.49M sh
Vanguard Portfolio Management, LLC 5.62% · 7.88M sh
Vanguard Capital Management, LLC 4.47% · 6.26M sh
Michael Weiss 3.50% · 4.90M sh
Opus Point Partners 3.48% · 4.87M sh
Geode Capital Management, LLC 2.64% · 3.70M sh
D. E. Shaw & Co., L.P. 2.43% · 3.40M sh
Soleus Capital Management, L.P. 2.09% · 2.93M sh
T. Rowe Price Group, Inc. 1.98% · 2.77M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

47 filings tracked · 21 buys · 26 sells

NameRoleStake
Michael Weiss Chairperson & CEO 3.50%
Sean Power CFO, Corporate Secretary & Treasurer 0.49%
Kenneth Hoberman Independent Director 0.20%
Yann Echelard Independent Director 0.16%
Daniel Hume Independent Director 0.14%
Laurence Charney Lead Independent Director 0.12%
Sagar Lonial Independent Director 0.07%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-09 Laurence Charney Lead Independent Director Open Market Disposition -5,000 $54.96
2026-08-06 Laurence Charney Lead Independent Director Other Disposition -6,050 --
2026-06-10 Laurence Charney Lead Independent Director Other Derivative Acquisition +8,325 --
2026-06-10 Kenneth Hoberman Independent Director Other Derivative Acquisition +8,325 --
2026-06-10 Yann Echelard Independent Director Other Derivative Acquisition +8,325 --
2026-06-10 Sagar Lonial Independent Director Other Derivative Acquisition +8,325 --
2026-06-10 Daniel Hume Independent Director Other Derivative Acquisition +8,325 --
2026-01-28 Laurence Charney Lead Independent Director Other Disposition -43,197 --
2026-01-07 Michael Weiss Chairperson & CEO Other Acquisition +622,000 --
2026-01-07 Sean Power CFO, Corporate Secretary & Treasurer Other Acquisition +90,000 --
2025-11-23 Yann Echelard Independent Director Open Market Disposition -5,000 $32.57
2025-11-04 Michael Weiss Chairperson & CEO Other Disposition -4,668,843 --
2025-09-10 Sagar Lonial Independent Director Open Market Disposition -20,852 $32.24
2025-06-12 Yann Echelard Independent Director Open Market Disposition -10,000 $36.94
2025-06-11 Laurence Charney Lead Independent Director Other Acquisition +21,408 --
2025-06-11 Kenneth Hoberman Independent Director Other Acquisition +14,718 --
2025-06-11 Yann Echelard Independent Director Other Acquisition +14,718 --
2025-06-11 Sagar Lonial Independent Director Other Acquisition +14,718 --
2025-06-11 Daniel Hume Independent Director Other Acquisition +14,718 --
2025-03-16 Daniel Hume Independent Director Other Disposition -62,459 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.

TG Therapeutics discussion 0 comments

Add a comment